Current and future trends in tuberculosis

Tuberculosis has shown higher rate of mortality than HIV because bacteria undergoes genetic mutation and forms resistance to present effective antibiotics. In 2013 WHO detected multiple drug resistance of 480,000 cases. There has been a great success in effective techniques in preventive care, infection care and treatment. Annual mortality rate has decreased since 1990. A sequence of international clinical trials by The British Medical council research, a four drug regimen was given for use in recently diagnosed tuberculosis patient. In latest research techniques of vaccines or new drug development are used to reduce risk in latently infected people. Despite of increasing funds in tuberculosis only 20 clinical trials of drugs and 12 vaccines are conducted.

  • Current global distribution in TB
  • Antibiotic resistance
  • New TB bio markers
  • Drugs under trials

Related Conference of Current and future trends in tuberculosis

June 09-10, 2020

10th European Epidemiology and Public Health Congress

Istanbul, Turkey
August 19-20, 2020

European Summit on HIV, STD and STIs

Milan, Italy
September 28-29, 2020

13th Global Infections Conference

Singapore
October 5-6, 2020

12th Euro-Global Conference on Infectious Diseases

Vienna, Austria
November 05-06, 2020

9th Asia Pacific STD and Infectious Diseases Congress

Tokyo, Japan
February 15-16, 2021

8th International Congress on Infectious Diseases

London, UK
February 22-23, 2021

4th Global Experts Meeting on Infectious Diseases

Singapore City, Singapore

Current and future trends in tuberculosis Conference Speakers

Recommended Sessions

Related Journals

Are you interested in